Celldex Therapeutics Stock
Price
Target price
€17.20
€17.20
0.580%
0.1
0.580%
€64.68
03.06.25 / Frankfurt
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Celldex Therapeutics Stock
The Celldex Therapeutics stock is trending slightly upwards today, with an increase of €0.10 (0.580%) compared to yesterday's price.
With 23 Buy predictions and not a single Sell prediction Celldex Therapeutics is an absolute favorite of our community.
Based on the current price of 17.2 € the target price of 64 € shows a potential of 272.09% for Celldex Therapeutics which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 0.580% | -4.469% | -6.044% | -44.839% | -29.339% | -18.726% | 573.228% |
| Vaxart Inc. | 8.680% | -3.929% | -1.411% | -48.391% | -45.363% | -88.494% | - |
| Larimar Therapeutics Inc. | 0.530% | 16.875% | -28.626% | -74.558% | -49.731% | -20.085% | -86.717% |
| aTyr Pharma Inc | 5.500% | 12.360% | 38.889% | 156.410% | 12.994% | 50.094% | 16.959% |
Comments
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at Morgan Stanley from $46.00 to $43.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat